Alternatives to Temodar If You Can't Fill Your Prescription

Temodar (temozolomide) is the cornerstone of treatment for glioblastoma multiforme (GBM) and anaplastic astrocytoma — but what happens when you can't get it? Whether due to a supply issue at your specialty pharmacy, an insurance denial, or a medical reason you can't tolerate it, knowing your options is critical.

This guide covers the most important alternatives to Temodar, when they are used, and what the evidence says. Always discuss any changes to your treatment plan with your neuro-oncologist.

Important: Don't Stop Treatment Without Talking to Your Doctor

If you cannot fill your Temodar prescription, contact your oncologist before missing a dose. For ongoing chemoradiation or maintenance cycles, a treatment delay is a serious concern. Your oncology team can often solve supply problems quickly — and if not, they can assess whether an alternative is appropriate for your specific situation.

1. Generic Temozolomide (Same Drug, Different Brand)

If brand Temodar is unavailable, the first "alternative" to ask about is generic temozolomide. It is FDA-approved as bioequivalent to brand Temodar and is manufactured by several companies including Teva, Sun Pharma, Dr. Reddy's, and Amneal. Generic temozolomide is significantly less expensive and is available through the same specialty pharmacy channels. This is typically the first switch your pharmacist or oncologist will make.

2. Lomustine (CCNU / CeeNU)

Lomustine (brand name CeeNU) is another alkylating agent in the nitrosourea class. It is an oral capsule taken every 6 weeks and is one of the most commonly used chemotherapy agents for recurrent glioblastoma. For patients with MGMT-methylated GBM, lomustine in combination with temozolomide (the "CCNU/TMZ" regimen) is now considered a standard first-line option. When temozolomide is unavailable, lomustine may be considered as a single agent for recurrent or refractory disease.

Lomustine carries its own toxicity profile, including significant myelosuppression and delayed nadir (blood count suppression peaks 4–6 weeks after dosing). It is not a simple swap — your oncologist must carefully evaluate whether it is appropriate for your situation.

3. Bevacizumab (Avastin)

Bevacizumab (brand name Avastin) is an anti-VEGF monoclonal antibody approved by the FDA for progressive (recurrent) glioblastoma. It is given as an intravenous infusion every 2 weeks. Bevacizumab improves progression-free survival and reduces the need for corticosteroids, though it has not consistently demonstrated an overall survival benefit in GBM.

Bevacizumab is typically used at recurrence rather than as a first-line replacement for temozolomide, but may be incorporated into treatment plans when Temodar is contraindicated or unavailable for a given patient.

38,717+ patients found their medications in stock

38K+

Find Temodar In Stock Today →

4. Procarbazine / PCV Regimen

The PCV regimen — procarbazine (Matulane), lomustine (CCNU), and vincristine — is an older combination chemotherapy regimen used primarily for anaplastic oligodendroglioma and some anaplastic astrocytomas. For patients with 1p/19q co-deleted anaplastic tumors, PCV is a proven standard of care. It may be considered when temozolomide is contraindicated or when a patient has progressed on temozolomide.

5. Carmustine / BCNU (BiCNU, Gliadel Wafer)

Carmustine (BCNU) is another nitrosourea alkylating agent available as an intravenous infusion (BiCNU) or as a polymer wafer (Gliadel) placed directly into the surgical cavity during tumor resection. The Gliadel wafer delivers carmustine locally to the tumor bed. Carmustine IV may be used in some recurrent GBM protocols. Like lomustine, it has significant myelosuppressive effects.

Skip the calls, skip the stress.

Find Temodar In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

6. Tumor Treating Fields (Optune)

While not a drug, Tumor Treating Fields (TTFields) via the Optune device is an FDA-approved treatment used alongside maintenance temozolomide for newly diagnosed GBM. The combination of TTFields + temozolomide extended median overall survival to 20.9 months compared to 16.0 months with temozolomide alone. If a temporary supply issue prevents your temozolomide cycle from starting on time, your oncologist may consider whether continuing TTFields alone during the gap is an option, though this is a highly individualized decision.

How to Talk to Your Doctor About Alternatives

When discussing alternatives with your neuro-oncologist, be sure to ask:

"What is my MGMT methylation status?" — this affects which alternatives are most effective

"Am I at a stage where bevacizumab is appropriate?"

"Are there clinical trials I'm eligible for?"

"How long can we wait before starting an alternative, if the supply issue is short-term?"

Before exploring alternatives, make sure you've exhausted every option to find your prescription. medfinder can contact pharmacies near you to locate available supply — saving you time when time matters most.

See also: How to Find Temodar in Stock Near You (Tools + Tips)